PMID- 30653031
OWN - NLM
STAT- MEDLINE
DCOM- 20210601
LR  - 20210601
IS  - 1533-4058 (Electronic)
IS  - 1533-4058 (Linking)
VI  - 28
IP  - 3
DP  - 2020 Mar
TI  - Transferred-tissue Microarray for Fluorescence In Situ Hybridization Test for 
      Human Epidermal Growth Factor Receptor 2 in Breast Cancer.
PG  - 187-193
LID - 10.1097/PAI.0000000000000742 [doi]
AB  - CONTEXT: Human epidermal growth factor receptor 2 (HER2) status of breast 
      carcinomas is usually determined by immunohistochemical (IHC) staining and, if 
      the IHC results are equivocal, in situ hybridization (ISH). Multiple ISH tests 
      are sometimes required for multiple primary or metastatic tumors. A method for 
      multiplex ISH test on tissues from multiple blocks is helpful in these 
      situations. OBJECT: To evaluate the clinical application of transferred-tissue 
      microarray (TTM) followed by a dual-probe HER2 fluorescence in situ hybridization 
      (FISH). DESIGN: A 3x3 TTM technique was successfully established using 152 
      invasive mammary carcinoma tissue fragments. To evaluate detection of HER2 
      positive tumors, this cohort was enriched with tumors with IHC scores of 2 and 3. 
      RESULTS: The HER2 FISH analyses revealed that all transferred-tissue fragments 
      were adequate for determining HER2 amplification. Tissue loss was minimal and had 
      no major adverse effects on interpretation of the test results. Of the 81 tumors 
      with IHC scores of 3, 72 (88.8%) were positive for HER2 FISH. The remaining 
      tumors were negative for HER2 FISH in both TTM and reflex whole tissue section. 
      Finally, FISH results for tumors with IHC scores of 2 were compared between TTM 
      and whole tissue section. Concordance was high in overall positivity/negativity 
      (100%), HER2 copy number (97.5%), and HER2/CEP17 ratio (100%). CONCLUSIONS: This 
      novel technique is a reliable option for performing multiple HER2 FISH tests 
      simultaneously in clinical and research-oriented settings with less tissue damage 
      compared with conventional tissue microarray techniques.
FAU - Lin, Chih-Hung
AU  - Lin CH
AD  - Department of Pathology, Kaohsiung Medical University Hospital.
AD  - Department of Pathology, College of Medicine, Kaohsiung Medical University, 
      Kaohsiung, Taiwan.
FAU - Wen, Chien-Hui
AU  - Wen CH
AD  - Department of Pathology, Kaohsiung Medical University Hospital.
FAU - Liu, Chia-Hsing
AU  - Liu CH
AD  - Department of Pathology, Kaohsiung Medical University Hospital.
FAU - Yang, Ching-Hsiu
AU  - Yang CH
AD  - Department of Pathology, Kaohsiung Medical University Hospital.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Appl Immunohistochem Mol Morphol
JT  - Applied immunohistochemistry & molecular morphology : AIMM
JID - 100888796
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - *Breast Neoplasms/genetics/metabolism/pathology
MH  - Female
MH  - Humans
MH  - *In Situ Hybridization, Fluorescence
MH  - *Receptor, ErbB-2/genetics/metabolism
MH  - Retrospective Studies
MH  - *Tissue Array Analysis
EDAT- 2019/01/18 06:00
MHDA- 2021/06/02 06:00
CRDT- 2019/01/18 06:00
PHST- 2019/01/18 06:00 [pubmed]
PHST- 2021/06/02 06:00 [medline]
PHST- 2019/01/18 06:00 [entrez]
AID - 00129039-202003000-00002 [pii]
AID - 10.1097/PAI.0000000000000742 [doi]
PST - ppublish
SO  - Appl Immunohistochem Mol Morphol. 2020 Mar;28(3):187-193. doi: 
      10.1097/PAI.0000000000000742.